VIDEO: GVHD pipeline 'very promising' for future treatments

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

The pipeline looks very promising for developing new drugs. There are several that are of interest to the field, and I await those results as these clinical trials continue to accrue patients and, hopefully, give us their results. Certain examples include the current trial of using alpha-1 antitrypsin in combination with steroids. I believe that trial has completed accrual, and I'm eager to see what those results look like, just because alpha-1 antitrypsin is such a well-tolerated drug and with such minimal side effects. The second agent that I'm interested in is apraglutide. This is based on the GLP-2 analog used to support intestinal homeostasis and is more regenerative therapy. The trial that is enrolling these patients, called the STARGAZE trial, has also completed accrual, so I'm eager to see what those results are. Once again, a drug that does not suppress the immune system and is focused on gut healing and acute-graft-versus host disease of the gut — very, very promising agent. And then I think the third one that I'm eager to think about and learn more about is itolizumab, which is the anti-CD6 treatment. I believe it's being studied in adults, but we always are eager to learn what the adult data looks like and how those can be translated to children.